JPML to Hear Oral Arguments Over Consolidation of Insulin Pricing Lawsuits Next Month

Five separate states have filed insulin pricing scheme lawsuits against drug manufacturers, and are calling for the cases to be consolidated in a Mississippi federal court.

A panel of federal judges will hear oral arguments next month, over whether to consolidate and centralize all insulin pricing lawsuits pending throughout the federal court system before one judge for coordinated discovery and pretrial proceedings.

Over the past few months, there have been a growing number of lawsuits against insulin manufacturers and other entities, alleging that there has been a widespread pricing scheme that has artificially increased the cost of the critical drug.

Insulin is a key treatment for diabetes, as it helps the body properly process, store and use glucose. Patients with Type 1 diabetes use insulin on a daily basis, and many with Type 2 diabetes also use insulin regularly to maintain proper blood glucose levels.

According to the lawsuits, insulin only costs about $2 per dose to produce, yet consumers and state medical plans are forced to pay $300 to $700 to purchase it, since drug manufacturers and pharmacy benefit managers (PBMs) have colluded to inflate prices.

Inflated Insulin Price Scheme

Lawsuits have been filed by a variety of different states, including Arkansas, Illinois, Kansas, Mississippi, Montana and others, seeking to hold the manufacturers and PBMs responsible for millions, and potentially billions, in damages caused by inflated costs paid by medical plans and consumers.

PBMs regularly release formulary lists of drugs insurers should be willing to pay for, which usually determines which drugs are sold on the U.S. market. However, the states allege manufacturers and PBMs have created a scheme where manufacturers pay high “administrative fees” to ensure their drugs get on those lists, which the lawsuit claims is a form of illegal rebate.

These fees, and other inflated prices, drive up the cost of insulin significantly, resulting in a drug that is only $2 to produce still costing consumers hundreds of dollars. The same insulin only cost $20 per vial as recently as the 1990s, and the cost to manufacture insulin has decreased since then, the lawsuits indicate.

Did You Know?

AT&T Data Breach Impacts Millions of Customers

More than 73 million customers of AT&T may have had their names, addresses, phone numbers, Social Security numbers and other information released on the dark web due to a massive AT&T data breach. Lawsuits are being pursued to obtain financial compensation.

Learn More

The insulin pricing problems are exacerbated by the fact that the three largest manufacturers, Eli Lilly, Novo Nordisk and Sanofi control 92% of insulin manufactured in the U.S. and receive 96% of the revenue of the global diabetes drug market. In turn, the three largest PBMs in the U.S., CVS Caremark, Express Scripts and OptumRX control more than 80% of the PBM market and the largest pharmacy chains in the U.S.

According to the American Diabetes Association, the cost of diabetes treatment in the U.S. cost about $327 billion in 2017, representing one out of every four dollars spent on healthcare in the U.S. that year.

Insulin Pricing Scheme Lawsuit Consolidation to be Considered

Last month, five states filed a motion for transfer with the U.S. Judicial Panel on Multidistrict Litigation (JPML), petitioning to have the complaints consolidated before one federal judge in the Southern District of Mississippi for coordinated discovery and pretrial proceedings.

In a Notice of Hearing Session (PDF) filed by the JPML on June 16, the judges indicate they will hear oral arguments on the consolidation of the five claims brought by Arkansas, Illinois, Kansas, Mississippi and Montana on July 27 at the Phillip Burton U.S. Courthouse in San Francisco, California.

Such consolidation is common in complex product liability lawsuits, where large numbers of cases are pending before different judges which involve similar injuries or damages caused by the same product.

If the JPML agrees to consolidate the cases before one judge for pretrial proceedings, they would create an insulin pricing scheme multidistrict litigation (MDL), where the cases would remain individual lawsuits filed by the state, but go through discovery, pre-trial motions, and potentially bellwether test cases. If, after the pretrial proceedings are concluded, the cases have not yet been resolved through a settlement agreement or other court action, they will be remanded back to their original District Courts for individual trials.


Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Leadership Development Committee for Suboxone Dental Injury Lawyers Established in Federal MDL
Leadership Development Committee for Suboxone Dental Injury Lawyers Established in Federal MDL (Posted yesterday)

The U.S. District Judge presiding over all Suboxone lawsuits has created a mentorship program to use the litigation to provide some attorneys an opportunity to gain experience in handling complex federal multidistrict litigations.

Gilead Settlement Resolves 2,625 HIV Drug Lawsuits Pending in Federal Courts for $40M
Gilead Settlement Resolves 2,625 HIV Drug Lawsuits Pending in Federal Courts for $40M (Posted 3 days ago)

Gilead says it will pay $40 million to resolve HIV drug lawsuits over Truvada, Atripla, Viread, Stribild and Complera pending in the federal court system, involving claims that the the company sat on safer formulations of the drugs for years to increase profits.